Desidustat is first-of-its-kind oral treatment for anemia associated with Chronic Kidney Disease (CKD) in India.
Under the terms of this agreement, Zydus has granted Sun Pharma semi-exclusive rights to comarket the product in India. Sun Pharma will market the drug under the brand name RYTSTAT®.
Zydus launched the drug under the brand name Oxemia™ in 2022 and will continue to market it. Zydus will receive upfront licensing income and is eligible to receive milestone income based on achievement of pre-defined milestones.
